Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

121.05USD
2:29am IST
Change (% chg)

$0.70 (+0.58%)
Prev Close
$120.35
Open
$120.60
Day's High
$121.69
Day's Low
$120.39
Volume
650,138
Avg. Vol
660,810
52-wk High
$149.17
52-wk Low
$96.18

Chart for

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $31,536.07
Shares Outstanding(Mil.): 223.19
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

Alexion, Elliott to jointly look for new director

Jan 2 Alexion Pharmaceuticals Inc said on Tuesday it had agreed to work with hedge fund Elliott Management to identify a new member to join the drugmaker's board.

03 Jan 2018

BRIEF-Alexion And Elliott Agree To Collaborate On Identifying A New Board Member

* ALEXION AND ELLIOTT AGREE TO COLLABORATE ON IDENTIFYING A NEW BOARD MEMBER

03 Jan 2018

UPDATE 2-Elliott Management seeks changes at Alexion - NYT

Dec 8 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

09 Dec 2017

CORRECTED-Elliott Management seeks changes at Alexion - NYT (Dec. 7)

Dec 7 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

08 Dec 2017

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

07 Dec 2017

BRIEF-Alexion receives new Japanese patent for Soliris

* Alexion receives new Japanese patent for Soliris® (eculizumab), extending patent protection into 2027 and strengthening global patent portfolio Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Alexion reports Q3 non-GAAP earnings per share of $1.44

* Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S

26 Oct 2017

RPT-BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

14 Sep 2017

BRIEF-Interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

14 Sep 2017

Alexion Pharma to lay off 20 percent of workforce

Alexion Pharmaceuticals Inc said on Tuesday it would lay off about 20 percent of its workforce and sharpen its focus on its core rare disease drugs business, as it looks to restore investor confidence.

12 Sep 2017

Competitors

Earnings vs. Estimates